Marina Biotech makes organisational changes
Creates the position of executive vice president of r&d
Richard Ho has joined the firm in the newly created position of executive vice president, Research and Development.
In addition, Philip Ranker has become interim chief financial officer, replacing Peter Garcia who has resigned from the role to pursue other opportunities.
Barry Polisky has moved from chief scientific officer to distinguished scientist and has become chairman of the firm's Scientific Advisory Panel and Michael Templin has been promoted to the newly created position of senior vice president and chief technology officer.
Finally, Alan Dunton has joined the firm as consulting chief medical officer.
Marina Biotech’s goal is to improve human health through the development of RNAi and RNA-based compounds and drug delivery technologies.
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development
AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment
AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy